These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23060293)

  • 1. Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.
    Santra S; Gogoi S; Gopishetty B; Antonio T; Zhen J; Reith ME; Dutta AK
    ChemMedChem; 2012 Dec; 7(12):2093-100. PubMed ID: 23060293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.
    Zhang S; Fernandez F; Hazeldine S; Deschamps J; Zhen J; Reith ME; Dutta AK
    J Med Chem; 2006 Jul; 49(14):4239-47. PubMed ID: 16821783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.
    Gopishetty B; Hazeldine S; Santra S; Johnson M; Modi G; Ali S; Zhen J; Reith M; Dutta A
    J Med Chem; 2011 Apr; 54(8):2924-32. PubMed ID: 21446715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
    Dutta AK; Ghosh B; Biswas S; Reith ME
    Eur J Pharmacol; 2008 Jul; 589(1-3):73-9. PubMed ID: 18561912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.
    Sharma H; Santra S; Debnath J; Antonio T; Reith M; Dutta A
    Bioorg Med Chem; 2014 Jan; 22(1):311-24. PubMed ID: 24315194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.
    Santra S; Sharma H; Vedachalam S; Antonio T; Reith M; Dutta A
    Bioorg Med Chem; 2015 Feb; 23(4):821-8. PubMed ID: 25593099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner.
    Zhang S; Zhen J; Reith ME; Dutta AK
    J Med Chem; 2005 Jul; 48(15):4962-71. PubMed ID: 16033275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
    Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
    PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.
    Dutta AK; Gopishetty B; Gogoi S; Ali S; Zhen J; Reith M
    Eur J Pharmacol; 2011 Dec; 671(1-3):39-44. PubMed ID: 21963455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Potent Dopamine-Norepinephrine and Triple Reuptake Uptake Inhibitors Based on Asymmetric Pyran Template and Their Molecular Interactions with Monoamine Transporters.
    Santra S; Kortagere S; Vedachalam S; Gogoi S; Antonio T; Reith MEA; Dutta AK
    ACS Chem Neurosci; 2021 Apr; 12(8):1406-1418. PubMed ID: 33844493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
    Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
    J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The extracts of Fructus Akebiae, a preparation containing 90% of the active ingredient hederagenin: serotonin, norepinephrine and dopamine reuptake inhibitor.
    Jin ZL; Gao N; Zhou D; Chi MG; Yang XM; Xu JP
    Pharmacol Biochem Behav; 2012 Jan; 100(3):431-9. PubMed ID: 22005599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and preliminary SAR study of 3- and 6-side-chain-extended tetrahydro-pyran analogues of cis- and trans-(6-benzhydryl-tetrahydropyran-3-yl)-benzylamine.
    Zhang S; Zhen J; Reith ME; Dutta AK
    Bioorg Med Chem; 2006 Jun; 14(11):3953-66. PubMed ID: 16481172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
    Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
    Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.
    Dutta AK; Fei XS; Beardsley PM; Newman JL; Reith ME
    J Med Chem; 2001 Mar; 44(6):937-48. PubMed ID: 11300876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors.
    Tamiz AP; Bandyopadhyay BC; Zhang J; Flippen-Anderson JL; Zhang M; Wang CZ; Johnson KM; Tella S; Kozikowski AP
    J Med Chem; 2001 May; 44(10):1615-22. PubMed ID: 11334571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
    Verrico CD; Miller GM; Madras BK
    Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters.
    Zhang S; Zhen J; Reith ME; Dutta AK
    Bioorg Med Chem; 2004 Dec; 12(23):6301-15. PubMed ID: 15519172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further structurally constrained analogues of cis-(6-benzhydrylpiperidin-3-yl)benzylamine with elucidation of bioactive conformation: discovery of 1,4-diazabicyclo[3.3.1]nonane derivatives and evaluation of their biological properties for the monoamine transporters.
    Kolhatkar R; Cook CD; Ghorai SK; Deschamps J; Beardsley PM; Reith ME; Dutta AK
    J Med Chem; 2004 Oct; 47(21):5101-13. PubMed ID: 15456254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.
    Froimowitz M; Wu KM; Moussa A; Haidar RM; Jurayj J; George C; Gardner EL
    J Med Chem; 2000 Dec; 43(26):4981-92. PubMed ID: 11150168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.